Popular Articles

PAION AG: Phase Ib And IIa Studies Of The Anesthetic/Sedative CNS 7056 On Track
The biopharmaceutical company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8) today announces that the respective Data Monitoring Committees (DMCs), after predefined interim analyses, recommended that the Company should proceed as planned with their Phase IIa study as well as Phase Ib of CNS 7065, a new short-acting intravenous anesthetic/sedative.
generic viagra online
Higher Drinking Age Linked To Less Binge Drinking...except In College Students
New research from Washington University School of Medicine in St. Louis has found substantial reductions in binge drinking since the national drinking age was set at 21 two decades ago, with one exception: college students. The rates of binge drinking in male collegians remain unchanged, but the rates in female collegians have increased dramatically.
News of the day
SYMBICORT(R) Added To Tiotropium Provided Clinically Significant Benefits For Patients With Severe COPD
Data presented at this year"s American Thoracic Society (ATS) congress, demonstrated that SYMBICORT® (budesonide/formoterol-TURBUHALER®, a dry powder inhaler) added to SpirivaTM (tiotropium) provided greater clinical improvements than tiotropium alone over a 12-week treatment period.1,2
Cardiovascular

Repeated Stress Signals Made In Cells With Metabolism-Associated Disease Encourage The Growth Of Invading Bacteria

Mitochondrial diseases disrupt the power generating machinery within cells and increase a person"s susceptibility to bacterial infection, particularly in the lungs or respiratory tract. A new study published in Disease Models & Mechanisms (DMM), shows that infection with the pneumonia causing bacteria Legionella, is facilitated by an increased amount of a signaling protein that is associated with mitochondrial disease. Patients with mitochondrial disease exhibit a wide range of symptoms including diabetes, blindness, deafness, stroke-like episodes, epilepsy, ataxia, muscle weakness and kidney disease. The metabolic abnormalities that cause these effects also induce a stress signal intended to help the body overcome its energy deficit. The stress-signal induces the production of more mitochondria, the energy generating "powerplants" of the body, in the hopes that more mitochondria will result in a better power supply. Researchers now show that the stress-signal associated with mitochondrial disease facilitates the growth and reproduction of the lung-infecting bacteria, Legionella. Cells with mitochondrial disease increase their production of a signaling protein called AMP-activated protein kinase (AMPK), to promote the generation of more energy producing mitochondria. Infectious bacteria, like Legionella, target the mitochondria and might use them to supplement their own needs and survival requirements. By manipulating AMPK levels, scientists were able to directly influence the ability of bacteria to replicate inside of the single-celled organism, Dictyostelium. Striking similarities that exist between simple organisms like Dictyostelium and humans allow scientists to use them to understand human disease. Dictyostelium is a free-living amoeba whose rapid movements make it useful to study motility and energy regulation, and in this case, the association between energy regulation and susceptibility to infection. Like humans, Dictyostelium can be infected by Legionella and quickly responds by producing a host of metabolism-associated proteins. Another similarity between humans and Dictyostelium is that both use AMPK as an internal sensor to coordinate energy synthesis with energy needs. However, unlike humans, researchers can infect Dictyostelium with germs like Legionella in a controlled environment and determine the influence of various parameters on the course of infection. The report titled "Legionella pneumophila multiplication is enhanced by chronic AMPK signalling in mitochondrially diseased cells" was written by Lisa Francione, Paige K. Smith, Sandra L. Accari, Paul B. Bokko and Paul Fisher at La Trobe Univeristy in Australia, Salvatore Bozzaro at University of Turin in Italy and Phillip E Taylor and Peter L. Beech at Deakin University in Australia. The study is published in the September/October 2009 issue of the new research journal, Disease Models & Mechanisms (DMM), published by The Company of Biologists, a non-profit based in Cambridge, UK. Kristy Kain The Company of Biologists


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):